From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Past Events

One-Stop Resource Helps Patients and Healthcare Providers Link to COVID-19 Clinical Trials and Expanded Access Programs
To help patients, caregivers, physicians, and other healthcare providers find COVID-19 treatment resources as quickly and easily as possible, the Reagan-Udall Foundation for the FDA today launched the onl
Reagan-Udall Foundation for the FDA Names Susan Winckler as CEO
The Reagan-Udall Foundation for the Food and Drug Administration has named
Food Industry Leader Molly Fogarty Named to Board of Directors
Molly Fogarty, Senior Vice President of Nestlé in the U.S., has been appointed to the Board of Directors for the Reagan-Udall Foundation for the Food and Drug Administration.
Nominations now closed
2019 Innovations in Regulatory Science Awards Dinner Highlights
Winners of 2019 Innovations in Regulatory Science Awards Announced
FDA’s Theresa Mullin, Compassionate Use Advisory Committee, and Cystic Fibrosis Foundation to be Honored with Innovations in Regulatory Science Awards  Honorees to be recognized on December 11 in Washington
Duke's Hernandez Appointed to Reagan-Udall Foundation Board of Directors
The Reagan-Udall Foundation for the Food and Drug Administration has named Dr. Adrian F. Hernandez to its Board of Directors.
Reagan-Udall Foundation for the FDA invites Nominations for IMEDS Steering Committee
The Reagan-Udall Foundation for the FDA seeks nominations for key positions on its Steering Committee.
FDA Eases Access to Unapproved Cancer Drugs - OBR Daily
"Patients with cancer are treated with drugs already approved by the U.S. Food and Drug Administration (FDA) or with an investigational agent in a clinical trial.
Project Facilitate: FDA’s Plan to Ease Expanded Access to Novel Therapies - The ASCO Post
The U.S. Food and Drug Administration (FDA) plans to provide oncologists with greater help in acquiring expanded access to investigational therapies.